Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MULTIPLE SCLEROSIS

Assessing long-term effectiveness of MS treatment — a matter of debate

Nature Reviews Neurology volume 17, pages 197–198 (2021)Cite this article

Subjects

Assessment of the long-term effectiveness of disease-modifying therapies in multiple sclerosis is plagued by methodological issues, but statistical methods continue to evolve. Use of a novel approach has highlighted the importance of accounting for cumulative exposure to disease-modifying therapies when assessing the long-term effects of treatment on disability accumulation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rollot, F. et al. Cumulative effects of therapies on disability in relapsing multiple sclerosis. Mult. Scler. https://doi.org/10.1177/1352458520980366 (2021).

    Article  PubMed  Google Scholar 

  2. Cohen, J. A. et al. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult. Scler. 26, 23–37 (2020).

    Article  Google Scholar 

  3. Trojano, M. et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat. Rev. Neurol. 13, 105–118 (2017).

    Article  Google Scholar 

  4. Abrahamowicz, M. et al. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J. Clin. Epidemiol. 59, 393–403 (2006).

    Article  Google Scholar 

  5. Sylvestre, M.-P. & Abrahamowicz, M. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat. Med. 28, 3437–3453 (2009).

    Article  Google Scholar 

  6. Vukusic, S. et al. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Mult. Scler. 26, 118–122 (2020).

    Article  Google Scholar 

  7. Robins, J. M., Hernán, M. A. & Brumback, B. Marginal structural models and causal inference in epidemiology. Epidemiology 11, 550–560 (2000).

    Article  CAS  Google Scholar 

  8. Karim, M. E. et al. Marginal structural Cox models for estimating the association between beta-interferon exposure and disease progression in a multiple sclerosis cohort. Am. J. Epidemiol. 180, 160–171 (2014).

    Article  Google Scholar 

  9. Kalincik, T. et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology 96, e783–e797 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Basic Medical Sciences, Neurological Sciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy

    Maria Trojano & Pietro Iaffaldano

Authors
  1. Maria Trojano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pietro Iaffaldano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Trojano.

Ethics declarations

Competing interests

M.T. has received research grants for her Institution from Biogen, Merck, Novartis and Roche, and honoraria as a speaker and advisory board member from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. P.I. has served on advisory boards for Biogen, Bayer, Genzyme, Merck Serono, Novartis, Roche and Teva and has received honoraria as a speaker from Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi Aventis and Teva.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trojano, M., Iaffaldano, P. Assessing long-term effectiveness of MS treatment — a matter of debate. Nat Rev Neurol 17, 197–198 (2021). https://doi.org/10.1038/s41582-021-00476-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-021-00476-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing